Egetis Therapeutics: Continued progress in Q4

Research Update

2024-02-23

09:30

Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.

FT

Fredrik Thor

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.